Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;76(3):2257-2272.
doi: 10.1007/s12070-024-04565-3. Epub 2024 Mar 10.

Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics

Ruby Dwivedi  1 , Ayushi Jain  1 , Shalini Gupta  1 , Shaleen Chandra  2
Affiliations

Immunotherapy: The Fourth Domain in Oral Cancer Therapeutics

Ruby Dwivedi et al. Indian J Otolaryngol Head Neck Surg. 2024 Jun.

Abstract

Owing to high global prevalence, incidence and associated mortality, cancer of head and neck particularly oral cancer remains a cardinal domain for research and trials. Immune-modulatory therapies that employ patients own immune system for therapeutic benefits in oral cancer seems promising. The aim of this review is to gauge the potential of immunotherapy as fourth domain of Oral cancer therapeutics. Articles were searched using suitable search terms in MEDLINE and Google Scholar database to include clinical trials, meta-analyses, and research in humans/animals/cell lines published in peer reviewed journals. A total of 97 articles were included in this review. Literature has several studies and trials where different types of immunotherapies has been attempted but it is crucial to identify precise biomarkers of genome based targeted agents and to find parameters to select patients who might benefit from immunotherapy. Also further research is required to estimate predictive value of tumor mutational burden and mutational signatures so as to aid in personalized prediction of oral cancer therapeutic response.

Keywords: Head and neck cancer; Immunotherapy; Oral cancer; PDL-1; Pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare that they have no conflict of interest.

Similar articles

See all similar articles

References

    1. https://gco.iarc.fr/today/data/factsheets/cancers/1-Lip-oral-cavity-fact... [accessed 09 Oct,2023]
    1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. doi: 10.1158/2159-8290.CD-21-1059. - DOI - PubMed
    1. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10(11):3755–3762. doi: 10.1158/1078-0432.CCR-04-0054. - DOI - PubMed
    1. Bauernhofer T, Kuss I, Henderson B, Baum AS, Whiteside TL. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol. 2003;33(1):119–124. doi: 10.1002/immu.200390014. - DOI - PubMed
    1. Dasgupta S, Bhattacharya-Chatterjee M, O’Malley BW, Chatterjee SK. Inhibition of NK cell activity through TGF-β1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol. 2005;175(8):5541–5550. doi: 10.4049/jimmunol.175.8.5541. - DOI - PubMed